Trial · NCT00349921

Clonidine Versus Adenosine to Treat Neuropathic Pain

NCT00349921, Phase 2, Completed, Wake Forest University Health Sciences; results first posted 2014-02-26

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Clonidine Versus Adenosine to Treat Neuropathic Pain. Trials, record NCT00349921. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00349921

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Clonidine Versus Adenosine to Treat Neuropathic Pain
NCT number: NCT00349921
Status: Completed
Phases: Phase 2
Enrollment: 24 participants, actual
Lead sponsor: Wake Forest University Health Sciences
Conditions: Pain
Interventions: clonidine, adenosine, placebo, placebo
First posted: 2006-07-10
Last updated: 2018-09-10
Results first posted: 2014-02-26

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Number Meeting Success Criterion	baseline and 2 hours	Verbal pain report 2 hours post injection compared to baseline verbal pain scores prior to injection

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Number Meeting Success Criterion	baseline and 2 hours	The primary outcome measure will be % change in pain report 2 hr following injection, using a response criterion of 30% reduction in ongoing pain.	participants meeting success criterion	NUMBER

Source ClinicalTrials.gov

Results by group3

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Units
Number Meeting Success Criterion	Clonidine	10	participants meeting success criterion
Number Meeting Success Criterion	Adenosine	5	participants meeting success criterion
Number Meeting Success Criterion	Placebo	0	participants meeting success criterion

Source ClinicalTrials.gov

Participant flow24

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
First Spinal Injection	STARTED	Clonidine First, Then Adenosine	10
First Spinal Injection	STARTED	Adenosine First, Then Clonidine	10
First Spinal Injection	STARTED	Clonidine First, Then Placebo	1
First Spinal Injection	STARTED	Adenosine First, Then Placebo	1
First Spinal Injection	COMPLETED	Clonidine First, Then Adenosine	9
First Spinal Injection	COMPLETED	Adenosine First, Then Clonidine	10
First Spinal Injection	COMPLETED	Clonidine First, Then Placebo	0
First Spinal Injection	COMPLETED	Adenosine First, Then Placebo	1
First Spinal Injection	NOT COMPLETED	Clonidine First, Then Adenosine	1
First Spinal Injection	NOT COMPLETED	Adenosine First, Then Clonidine	0

1 to 10 of 24Source ClinicalTrials.gov

See all 24 participant flow

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals12

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Clonidine First, Then Adenosine
Total, all-cause mortality	Adenosine First, Then Clonidine
Total, all-cause mortality	Clonidine First, Then Placebo
Total, all-cause mortality	Adenosine First, Then Placebo
Total, other adverse events	Clonidine First, Then Adenosine	0	11
Total, other adverse events	Adenosine First, Then Clonidine	0	11
Total, other adverse events	Clonidine First, Then Placebo	0	1
Total, other adverse events	Adenosine First, Then Placebo	0	1
Total, serious adverse events	Clonidine First, Then Adenosine	0	11
Total, serious adverse events	Adenosine First, Then Clonidine	0	11

1 to 10 of 12Source ClinicalTrials.gov

See all 12 adverse event totals

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
P01NS041386	Pharmacologic Plasticity in the Presence of Pain	EISENACH, JAMES	WAKE FOREST UNIVERSITY HEALTH SCIENCES	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE	2002 to 2006

Source NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00349921

GET https://conductscience.org/api/trials/v1/NCT00349921/flow?page=2

API reference For AI assistants